Analyst Stock Ratings Initiations

Buy NowGet Alert
05/02/2025GPCRBuy Now
Structure Therapeutics
$27.09121.48%Citigroup
Samantha Semenkow34%
 → $60Initiates → BuyGet Alert
05/02/2025CGONBuy Now
CG Oncology
$29.0541.14%JP Morgan
Brian Cheng37%
 → $41Initiates → OverweightGet Alert
05/01/2025AVPTBuy Now
AvePoint
$17.0811.24%Scotiabank— → $19Initiates → Sector OutperformGet Alert
05/01/2025RADXBuy Now
Radiopharm Theranostics
$4.19186.39%Maxim Group
Michael Okunewitch27%
 → $12Initiates → BuyGet Alert
05/01/2025HUTBuy Now
Hut 8
$14.0042.86%Maxim Group
Matthew Galinko43%
 → $20Initiates → BuyGet Alert
05/01/2025NOTEBuy Now
FiscalNote Holdings
$0.66281.68%Ladenburg Thalmann
Glenn Mattson68%
 → $2.5Initiates → BuyGet Alert

Recent Analyst Stock Rating Initiation News

UBS Maintains Neutral on Viavi Solutions, Lowers Price Target to $11
UBS analyst Andrew Spinola maintains Viavi Solutions (NASDAQ:VIAV) with a Neutral and lowers the price target from $11.5 to $11.
UBS Maintains Buy on Twilio, Lowers Price Target to $150
UBS analyst Taylor McGinnis maintains Twilio (NYSE:TWLO) with a Buy and lowers the price target from $175 to $150.
UBS Maintains Neutral on Atlassian, Lowers Price Target to $215
UBS analyst Karl Keirstead maintains Atlassian (NASDAQ:TEAM) with a Neutral and lowers the price target from $230 to $215.
UBS Maintains Neutral on Open Text, Lowers Price Target to $28
UBS analyst Seth Gilbert maintains Open Text (NASDAQ:OTEX) with a Neutral and lowers the price target from $32 to $28.
UBS Maintains Neutral on Utz Brands, Lowers Price Target to $13.5
UBS analyst Peter Grom maintains Utz Brands (NYSE:UTZ) with a Neutral and lowers the price target from $15 to $13.5.
UBS Maintains Neutral on Hershey, Lowers Price Target to $170
UBS analyst Peter Grom maintains Hershey (NYSE:HSY) with a Neutral and lowers the price target from $175 to $170.
UBS Maintains Buy on Freshworks, Lowers Price Target to $19
UBS analyst Taylor McGinnis maintains Freshworks (NASDAQ:FRSH) with a Buy and lowers the price target from $22 to $19.
UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $41
UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:CYTK) with a Neutral and lowers the price target from $47 to $41.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free

Connect With Us

instagramlinkedinyoutube

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2025 Benzinga | All Rights Reserved